Mineralys Therapeutics, Inc.

1. 01

   Behind SPY and its sector fund XLV over 1 year

   1 month: −22.6% (SPY −1.6%, XLV +13.5%). 3 months: −36.7% (SPY −0.4%, XLV +15.5%). 1 year: −57.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: MLYS, SPY and XLV · as of 4 Nov 2026

2. 02

   10.9% above its 52-week low

   Closed at $17.00 on 4 Nov 2026: 64.3% below the 52-week high of $47.65 (12 Nov 2025) and 10.9% above the low of $15.33 (3 Nov 2026).

   Daily price bars, split-adjusted · as of 4 Nov 2026

3. 03

   5.3 days to cover short interest

   7.4M shares were sold short at the 15 Oct 2026 settlement, 8.4% of the 88.4M shares outstanding; covering them would take 5.3 days of average volume. Short interest is reported twice a month, on a lag.

   Exchange short-interest filing · as of 15 Oct 2026

4. 04

   Volume 3.1× its 30-session average on 2 Nov 2026

   2 Nov 2026 volume of 4.6M shares was 3.1× the average of the 30 sessions before it (1.5M), as the price fell 14.5%. SPY traded 1.2× its own average that session.

   Daily volume against a 30-session baseline · as of 2 Nov 2026

5. 05

   Below its 50- and 200-day averages

   The 4 Nov 2026 close of $17.00 was 29.8% below its 50-day average ($24.20) and 36.5% below its 200-day average ($26.75). It has closed below the 200-day for 31 sessions, since 23 Sep 2026. The 50-day average crossed below the 200-day on 24 Mar 2026, 156 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

At the 4 Nov 2026 close